Medibank Private Limited

MPL is trading at AU$4.81, which is more than 20% below its estimated future cash flow value of AU$6.73, suggesting significant upside potential. Its Price-to-Earnings ratio of 28.6x also compares favorably against the peer average of 32.2x, indicating relative undervaluation within its competitive set.

MPL's Price-to-Earnings ratio of 28.6x is substantially higher than the Global Insurance industry average of 11.7x, and exceeds the estimated fair P/E ratio of 20.5x, signaling overvaluation on an industry-wide basis. A community analyst narrative also places fair value at just AU$3.83, implying the stock is currently overvalued.

MPL is forecast to grow earnings at 9% per annum and EPS at 9.2% per annum, comfortably exceeding the savings rate of 2.7%. Return on equity is projected to reach a high 25.8% in three years, pointing to strong capital efficiency and compounding shareholder value over the medium term.

Despite positive absolute growth forecasts, MPL's projected earnings growth of 9% per year and revenue growth of 4.6% per year both fall short of the broader Australian market's expected rates of 11.7% and 5.8% respectively, raising concerns about underperformance relative to market alternatives.

A broad coverage base of 20–21 analysts follows MPL, with the consensus 12-month price target of AU$5.03–AU$5.09 representing a meaningful premium over recent trading prices near AU$4.38–AU$4.81. The high end of analyst targets reaches AU$6.15, reflecting strong conviction from some analysts about material upside.

The analyst consensus price target implies less than 20% upside from current share price levels, a threshold that typically signals limited near-term catalysts. The low end of analyst price targets sits at AU$4.50–AU$4.60, close to current trading levels, reflecting significant disagreement and cautious positioning among parts of the analyst community.